Lilly to acquire Ajax Therapeutics to advance outcomes for patients with myelofibrosis and polycythemia vera - PR Newswire

/PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Ajax Therapeutics, Inc. ("Ajax"), a biopharmaceutical company developing next generation JAK inhibitors...

You are being redirected to the original discussion. Please continue if you want to read the full post.

Continue to original article

You will be redirected in 3 seconds.